Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial

Gilmar Reis, Eduardo Augusto Dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Gurmit Singh, Jay J H Park, Jamie I Forrest, Ofir Harari, Castilho Vitor Quirino Dos Santos, Ana Paula Figueiredo Guimarães de Almeida, Adhemar Dias de Figueiredo Neto, Leonardo Cançado Monteiro Savassi, Aline Cruz Milagres, Mauro Martins Teixeira, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Edward J Mills, TOGETHER Investigators, Gilmar Reis, Eduardo Augusto Dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Gurmit Singh, Jay J H Park, Jamie I Forrest, Ofir Harari, Castilho Vitor Quirino Dos Santos, Ana Paula Figueiredo Guimarães de Almeida, Adhemar Dias de Figueiredo Neto, Leonardo Cançado Monteiro Savassi, Aline Cruz Milagres, Mauro Martins Teixeira, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Edward J Mills, TOGETHER Investigators

Abstract

Importance: Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are needed.

Objective: To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting.

Design, setting, and participants: This randomized clinical trial was conducted in Brazil. Recently symptomatic adults diagnosed with respiratory symptoms from SARS-CoV-2 infection were enrolled between June 2 and September 30, 2020. The planned sample size was 1476 patients, with interim analyses planned after 500 patients were enrolled. The trial was stopped after the interim analysis for futility with a sample size of 685 patients. Statistical analysis was performed in December 2020.

Interventions: Patients were randomly assigned to hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days), lopinavir-ritonavir (loading dose of 800 mg and 200 mg, respectively, every 12 hours followed by 400 mg and 100 mg, respectively, every 12 hours for the next 9 days), or placebo.

Main outcomes and measures: The primary outcomes were COVID-19-associated hospitalization and death assessed at 90 days after randomization. COVID-19-associated hospitalization was analyzed with a Cox proportional hazards model. The trial included the following secondary outcomes: all-cause hospitalization, viral clearance, symptom resolution, and adverse events.

Results: Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median (range) age was 53 (18-94) years. A total of 214 participants were randomized to hydroxychloroquine; 244, lopinavir-ritonavir; and 227, placebo. At first interim analysis, the data safety monitoring board recommended stopping enrollment of both hydroxychloroquine and lopinavir-ritonavir groups because of futility. The proportion of patients hospitalized for COVID-19 was 3.7% (8 participants) in the hydroxychloroquine group, 5.7% (14 participants) in the lopinavir-ritonavir group, and 4.8% (11 participants) in the placebo group. We found no significant differences between interventions for COVID-19-associated hospitalization (hydroxychloroquine: hazard ratio [HR], 0.76 [95% CI, 0.30-1.88]; lopinavir-ritonavir: HR, 1.16 [95% CI, 0.53-2.56] as well as for the secondary outcome of viral clearance through day 14 (hydroxychloroquine: odds ratio [OR], 0.91 [95% CI, 0.82-1.02]; lopinavir-ritonavir: OR, 1.04 [95% CI, 0.94-1.16]). At the end of the trial, there were 3 fatalities recorded, 1 in the placebo group and 2 in the lopinavir-ritonavir intervention group.

Conclusions and relevance: In this randomized clinical trial, neither hydroxychloroquine nor lopinavir-ritonavir showed any significant benefit for decreasing COVID-19-associated hospitalization or other secondary clinical outcomes. This trial suggests that expedient clinical trials can be implemented in low-income settings even during the COVID-19 pandemic.

Trial registration: ClinicalTrials.gov Identifier: NCT04403100.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Flow Diagram of Participants in…
Figure 1.. Flow Diagram of Participants in the TOGETHER Trial
Figure 2.. Time to Hospitalization by Study…
Figure 2.. Time to Hospitalization by Study Group
Shaded areas indicate 95% CIs; HCQ, hydroxychloroquine; and L + R, lopinavir-ritonavir.

References

    1. Johns Hopkins University & Medicine . Coronavirus Resource Center. September 10, 2020. Accessed November 19, 2020.
    1. Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the treatment of Covid-19–preliminary report. N Engl J Med. 2020;383(10):992. doi:10.1056/NEJMc2022236
    1. Horby P, Lim WS, Emberson JR, et al. ; RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1101/2020.06.22.20137273
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
    1. Rayner CR, Dron L, Park JJH, et al. . Accelerating clinical evaluation of repurposed combination therapies for COVID-19. Am J Trop Med Hyg. 2020;103(4):1364-1366. doi:10.4269/ajtmh.20-0995
    1. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Glob Health. 2020;8(10):e1249-e1250. doi:10.1016/S2214-109X(20)30365-X
    1. Liu J, Cao R, Xu M, et al. . Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi:10.1038/s41421-020-0156-0
    1. Yao X, Ye F, Zhang M, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-739. doi:10.1093/cid/ciaa237
    1. Chen F, Chan KH, Jiang Y, et al. . In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69-75. doi:10.1016/j.jcv.2004.03.003
    1. Chan JF, Yao Y, Yeung ML, et al. . Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-1913. doi:10.1093/infdis/jiv392
    1. Abd-Elsalam S, Esmail ES, Khalaf M, et al. . Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103(4):1635-1639. doi:10.4269/ajtmh.20-0873
    1. RECOVERY Collaborative Group . Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-52. doi:10.1016/S0140-6736(20)32013-4
    1. Forrest JI, Rayner CR, Park JJH, Mills EJ. Early treatment of COVID-19 disease: a missed opportunity. Infect Dis Ther. 2020;9(4):715-720. doi:10.1007/s40121-020-00349-8
    1. Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13(3):358-366. doi:10.1177/1740774515626362
    1. Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1-8. doi:10.1016/j.jclinepi.2020.04.025
    1. Park JJH, Siden E, Zoratti MJ, et al. . Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572. doi:10.1186/s13063-019-3664-1
    1. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70. doi:10.1056/NEJMra1510062
    1. Dimairo M, Pallmann P, Wason J, et al. ; ACE Consensus Group . The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;369:m115. doi:10.1136/bmj.m115
    1. Dimairo M, Pallmann P, Wason J, et al. ; ACE Consensus Group . The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials. 2020;21(1):528. doi:10.1186/s13063-020-04334-x
    1. Chu HY, Englund JA, Starita LM, et al. ; Seattle Flu Study Investigators . Early detection of Covid-19 through a citywide pandemic surveillance platform. N Engl J Med. 2020;383(2):185-187. doi:10.1056/NEJMc2008646
    1. Barrett B, Brown R, Mundt M, et al. . The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid. J Clin Epidemiol. 2005;58(6):609-617. doi:10.1016/j.jclinepi.2004.11.019
    1. Powers JH III, Bacci ED, Leidy NK, et al. . Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI). PLoS One. 2018;13(3):e0194180. doi:10.1371/journal.pone.0194180
    1. Lieberman JA, Pepper G, Naccache SN, Huang ML, Jerome KR, Greninger AL. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol. 2020;58(8):e00821-20. doi:10.1128/JCM.00821-20
    1. Harari O, Hsu G, Dron L, Park JJH, Thorlund K, Mills EJ. Utilizing Bayesian predictive power in clinical trial design. Pharm Stat. 2020. doi:10.1002/pst.2073
    1. Santos J, Brierley S, Gandhi MJ, Cohen MA, Moschella PC, Declan ABL. Repurposing therapeutics for potential treatment of SARS-CoV-2: a review. Viruses. 2020;12(7):E705. doi:10.3390/v12070705
    1. Lee Z, Rayner CR, Forrest JI, Nachega JB, Senchaudhuri E, Mills EJ. The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19. Am J Trop Med Hyg. 2021;104(1):35-38. doi:10.4269/ajtmh.20-1320
    1. Hung IF, Lung KC, Tso EY, et al. . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-1704. doi:10.1016/S0140-6736(20)31042-4
    1. Mitjà O, Corbacho-Monné M, Ubals M, et al. ; BCN PEP-CoV-2 RESEARCH GROUP . Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020;ciaa1009. doi:10.1093/cid/ciaa1009
    1. Skipper CP, Pastick KA, Engen NW, et al. . Hydroxychloroquine in nonhospitalized adults with early COVID-19 : a randomized trial. Ann Intern Med. 2020;173(8):623-631. doi:10.7326/M20-4207
    1. Cohen MS. Hydroxychloroquine for the prevention of Covid-19 - searching for evidence. N Engl J Med. 2020;383(6):585-586. doi:10.1056/NEJMe2020388
    1. Pan H, Peto R, Henao-Restrepo AM, et al. . Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2020. doi:10.1056/NEJMoa2023184
    1. Boulware DR, Pullen MF, Bangdiwala AS, et al. . A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. doi:10.1056/NEJMoa2016638
    1. Drugs for Neglected Diseases Institute . The ANTICOV trial. Accessed December 5, 2020.
    1. . Trial of early therapies during non-hospitalized outpatient window for COVID-19 (TREATNOW). Accessed December 5, 2020.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera